Related Experiment Videos
Neonatal screening for metabolic and endocrine diseases
1Department of Pediatrics, Brooke Army Medical Center, San Antonio, Texas.
Insights
Newborn screening for metabolic diseases like PKU is crucial for early diagnosis and prevention of handicaps. These programs offer excellent cost-benefits and have significantly reduced conditions such as PKU-related mental retardation.
Area of Science:
- Medical Genetics
- Public Health
- Pediatrics
Background:
- Neonatal screening is vital for identifying infants with or at risk of metabolic diseases.
- Early diagnosis and intervention can prevent physical and mental handicaps.
Purpose of the Study:
- To highlight the importance of neonatal screening for metabolic diseases.
- To discuss the selection criteria, implementation, and benefits of screening programs.
Main Methods:
- Utilizes World Health Organization screening criteria for disease selection.
- Describes state-level laboratory testing for various metabolic disorders.
- Emphasizes the role of laboratory liaison and parental information in follow-up care.
Main Results:
- All states screen for phenylketonuria (PKU) and hypothyroidism.
- Significant numbers of states screen for galactosemia, maple syrup urine disease, and homocystinuria.
- Screening programs demonstrate excellent cost-benefit ratios (1:13 to 1:20).
- Screening has virtually eliminated mental retardation due to PKU.
Conclusions:
- Neonatal screening programs are highly effective in preventing serious health outcomes.
- Technological advancements promise improved and more comprehensive screening in the future.
- Effective follow-up care is essential for maximizing the benefits of screening.
Abstract:
The screening of neonates for metabolic diseases is important in order to identify a population with or at risk for metabolic diseases. Early diagnosis can then be made, treatment instituted and physical and/or mental handicaps due to the disease can be prevented. The World Health Organization's screening criteria are helpful in selecting those diseases appropriate for screening. Usually a state-designated central laboratory performs the screening tests. All states screen for phenylketonuria (PKU) and hypothyroidism; in addition, 26 states screen for galactosemia, 20 for maple syrup urine disease and 19 for homocystinuria. The cost-benefit ratio for screening programs is excellent, varying from 1:13 to 1:20. The necessary follow-up of patients for diagnosis and treatment can be enhanced by maintaining a close liaison with the laboratory and providing adequate information to parents. As a result of instituting a screening program, the incidence of mental retardation due to PKU has been practically eliminated and new insights about metabolic diseases have been obtained. The rapid progress in technology may soon result in better and cheaper tests capable of identifying more diseases amenable to treatment.